CTOs on the Move

Benitec Ltd

www.benitec.com

 
Benitec is a biotechnology company developing a proprietary therapeutic technology platform that combines RNA interference (RNAi) with gene therapy with a goal of providing sustained, long-lasting silencing of disease-causing genes from a single administration.
  • Number of Employees: 25-100
  • Annual Revenue: $0-1 Million

Executives

Name Title Contact Details
Sophie Mukadam
Chief Operating Officer Profile

Funding

Benitec Ltd raised $12.9M on 04/27/2021

Similar Companies

CymaBay

CymaBay Therapeutics is a clinical-stage biopharmaceutical company located in the San Francisco Bay Area focused on developing therapies to treat metabolic diseases with high unmet medical need or serious rare and orphan diseases. We are committed to developing breakthrough medicines that improve the lives of patients and their families. CymaBay was seeded with the assets from an earlier metabolic disease company in which more than $120M was invested to produce a robust pipeline.

Alpine Immune Sciences

Alpine Immune Sciences is a clinical stage biopharmaceutical company dedicated to discovering and developing innovative, protein-based immunotherapies targeting the immune synapse to treat autoimmune and inflammatory diseases. We have two products in the clinic for inflammatory diseases, collaborations with world-class partners, and a robust development pipeline. Traded on NASDAQ under ticker ALPN.

New England Peptide

New England Peptide is a Gardner, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Kowa Research Institute

Kowa Research Institute is a Morrisville, NC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Janpix

Janpix is discovering and developing monovalent small molecule degraders of Signal Transducer and Activator of Transcription (“STAT”) proteins. Most members of this family of transcription factors have been known for some time and the relevance of STAT3 & STAT5, in particular, in certain cancers is well validated. Although disrupting the function of STAT proteins is very challenging, Janpix has developed new chemistry to address this complex problem.